Enhertu pushes on the HER2-low door once again
Daiichi and AstraZeneca claim another breast cancer success, and further evidence of the ADC’s activity in very low HER2 expression.
Blueprint still sees an oncology future
Despite a growing presence outside cancer, the company wants to stay true to its “DNA”.
The month ahead: April’s upcoming events
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
ESMO 2023 – some Tropion fears allayed
However, lack of meaningful efficacy in Tropion-Lung01 suggests that datopotamab deruxtecan might be restricted to a histology-defined NSCLC subgroup.
